|
|
|
25.06.25 - 14:03
|
ORYZON to Host Virtual KOL Event on July 9, 2025 (GlobeNewswire EN)
|
|
|
To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat's Phase III PORTICO-2 trial in BPD To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat's Phase III PORTICO-2 trial in BPD...
|
|
|
|
|
23.06.25 - 14:03
|
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it has submitted the clinical trial protocol for its Phase III PORTICO-2 trial to the U.S. Food and Drug Administration (FDA) to initiate a registrational trial to evaluate vafidemstat in patients with Borderline Personality Disorder (BPD). The PORTICO-2 trial builds upon the encouraging results observed in the previous PORTICO Phase IIb study, where vafidemstat demonstrated significant and clinically meaningful reductions in secondary endpoints measuring aggression and overall BPD improvement. Aggression is a key symptom domain in BPD that currently represents a major unmet medical need and will be the primary endpoint in PORTICO-2. Vafidemstat, an orally active LSD1 inhibitor with a novel epigenetic mechanism of action, has shown a favorable safety and tolerability profile across multip...
|
|
|
17.06.25 - 14:03
|
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29 (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its Chief Scientific Officer, Dr. Jordi Xaus will be attending the 2025 Phelan-McDermid Syndrome Congress in Barcelona on June 26-29, which comprises the CureSHANK 2nd Annual Phelan-McDermid Syndrome Drug Development Symposium (PMSDDS2025) and the III Scientific Conference of the Spanish Phelan-McDermid Syndrome Association. Dr. Xaus will participate in a panel discussion within PMSDDS2025 entitled “Industry Perspectives Discussion”, as part of the morning session “Noncommercial & Commercial Clinical Trials and Business Considerations”, on June 27....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.05.25 - 06:09
|
TAGESVORSCHAU: Termine am 30. Mai 2025 (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX) - Wirtschafts- und Finanztermine am Freitag, den 30. Mai 2025^TERMINE UNTERNEHMEN06:55 DEU: Stratec, Q1-Zahlen08:00 CHE: Transocean, Hauptversammlung11:00 ESP: Iberdrola, HauptversammlungTERMINE KONJUNKTURBGR: ......
|
|
|
|
|
29.05.25 - 17:42
|
TAGESVORSCHAU: Termine am 30. Mai 2025 (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX) - Wirtschafts- und Finanztermine am Freitag, den 30. Mai 2025^TERMINE UNTERNEHMEN06:55 DEU: Stratec, Q1-Zahlen08:00 CHE: Transocean, Hauptversammlung11:00 ESP: Iberdrola, HauptversammlungTERMINE KONJUNKTURBGR: ......
|
|
|
|
|
|
|
|
|
|
|
13.05.25 - 13:06
|
ABBYY Drives Growth in EMEA With the Appointment of Arnaud Lagarde as New Vice President of Sales (Business Wire)
|
|
|
AUSTIN, Texas--(BUSINESS WIRE)--#AI--Today, the global leader in purpose-built AI for intelligent automation, ABBYY, appointed Arnaud Lagarde as its new Vice President of Sales for EMEA.
The appointment comes as ABBYY expands its EMEA leadership team with the goals of strengthening regional growth, deepening customer relationships, and accelerating the adoption of intelligent automation solutions across key markets.
Lagarde joins ABBYY from OctaiPipe, where he held the Chief Revenue Officer role. Over the last two decades, Lagarde has overseen over 100 automation and AI projects across major companies including Astra Zeneca, ING, Societe Generale, Telefonica, and UBS.
He brings extensive sales and domain expertise in AI-driven optimization, as well as strong experience in cutting-edge technologies, including Federated Learning, large language models (LLMs), reinforcement learning, and computer vision.
"Arnaud brings a rare combination of deep technical acumen and commercial leadership across AI, auto...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
